Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: anin silicobased approach
- 3 July 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Journal of Biomolecular Structure and Dynamics
- Vol. 39 (10), 3802-3811
- https://doi.org/10.1080/07391102.2020.1768902
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatmentviz.Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic. Communicated by Ramaswamy H. SarmaThis publication has 47 references indexed in Scilit:
- Coronaviruses: An Overview of Their Replication and PathogenesisPublished by Springer Science and Business Media LLC ,2015
- Molecular dynamics simulations: from structure function relationships to drug discoveryIn Silico Pharmacology, 2014
- In Silico Docking, Molecular Dynamics and Binding Energy Insights into the Bolinaquinone-Clathrin Terminal Domain Binding SiteMolecules, 2014
- Molecular dynamics simulations and drug discoveryBMC Biology, 2011
- Mechanism of the Maturation Process of SARS-CoV 3CL ProteaseJournal of Biological Chemistry, 2005
- UCSF Chimera?A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- PRODRG: a tool for high-throughput crystallography of protein–ligand complexesActa Crystallographica Section D-Structural Biology, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions"Protein Engineering, Design and Selection", 1995